SEC Comment Letter 0000000000-23-003229 to PURPLE BIOTECH LTD. (PPBT)
PURPLE BIOTECH LTD.
Date: March 30, 2023 · CIK: 0001614744 · Accession: 0000000000-23-003229
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-270769
Letter
United States securities and exchange commission logo March 30, 2023 Gil Efron Chief Executive Officer PURPLE BIOTECH LTD. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel Re:PURPLE BIOTECH LTD. Registration Statement on Form F-3 Filed March 23, 2023 File No. 333-270769 Dear Gil Efron: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jayun Koo, Esq.
Show Raw Text
United States securities and exchange commission logo
March 30, 2023
Gil Efron
Chief Executive Officer
PURPLE BIOTECH LTD.
4 Oppenheimer Street, Science Park
Rehovot 7670104, Israel
Re:PURPLE BIOTECH LTD.
Registration Statement on Form F-3
Filed March 23, 2023
File No. 333-270769
Dear Gil Efron:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jayun Koo, Esq.